MarketCap
Facebook
X
TelegramAnnual report 2025
added 01-30-2026
Vallon Pharmaceuticals ROA Ratio 2011-2026 | VLON
Annual ROA Ratio Vallon Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -137.96 | -143.0 | -441.04 | -839.95 | -111.61 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -111.61 | -839.95 | -334.71 |
Quarterly ROA Ratio Vallon Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -235.45 | -204.1 | -153.14 | -38.89 | -87.41 | -97.05 | -216.62 | -270.62 | -276.92 | -234.7 | -120.21 | -16.46 | -28.86 | -29.87 | -49.72 | -50.32 | -159.74 | -256.77 | -357.02 | -351.1 | -351.1 | -241.68 | -121.57 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -16.46 | -357.02 | -171.71 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M |  USA |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-76.23 | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-35.68 | - | 4.14 % | $ 49.1 M | USA |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-150.49 | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
-218.41 | - | - | $ 8.42 M | USA |
 |
Aptorum Group Limited
APM
|
-7.29 | $ 0.9 | 0.78 % | $ 6.62 M | China |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
19.07 | $ 22.6 | 1.35 % | $ 3.75 B | USA |
 |
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M |  Israel |
 |
Brainstorm Cell Therapeutics
BCLI
|
-1008.51 | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
26.14 | - | -4.8 % | $ 255 M | USA |
 |
AIkido Pharma
AIKI
|
-19.87 | - | 1.93 % | $ 17.4 M | USA |
 |
Cara Therapeutics
CARA
|
-56.79 | - | -3.03 % | $ 260 M | USA |
 |
CASI Pharmaceuticals
CASI
|
-26.5 | - | - | $ 35.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Fennec Pharmaceuticals
FENC
|
-13.81 | $ 6.78 | -1.02 % | $ 194 M | USA |
 |
ChromaDex Corporation
CDXC
|
16.34 | - | -0.88 % | $ 598 M | USA |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M |  Canada |
 |
Galectin Therapeutics
GALT
|
-157.87 | $ 2.34 | -1.48 % | $ 150 M | USA |
 |
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
-122.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-206.68 | - | 17.91 % | $ 11.1 M | USA |
 |
Genmab A/S
GMAB
|
22.5 | $ 26.37 | -1.01 % | $ 16.5 B |  Danmark |
 |
BioNTech SE
BNTX
|
65.02 | $ 101.6 | -0.45 % | $ 27.2 B | Germany |
 |
Checkpoint Therapeutics
CKPT
|
-752.78 | - | - | $ 169 M | USA |
 |
Avenue Therapeutics
ATXI
|
-99.25 | - | -52.27 % | $ 4.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
-52.23 | $ 4.1 | - | $ 438 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-3.73 | $ 23.28 | -0.6 % | $ 2.96 B | USA |
 |
Heron Therapeutics
HRTX
|
-7.89 | $ 1.23 | 3.39 % | $ 205 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-48.81 | $ 1.49 | 4.58 % | $ 397 M | Britain |
 |
Aptose Biosciences
APTO
|
-254.37 | - | -45.71 % | $ 1.2 M | Canada |
 |
ImmuCell Corporation
ICCC
|
-2.45 | $ 8.27 | 0.24 % | $ 74.6 M | USA |
 |
AstraZeneca PLC
AZN
|
0.11 | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
12.03 | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-103.3 | $ 2.9 | -0.64 % | $ 4.77 M | Israel |
 |
Innate Pharma S.A.
IPHA
|
-19.74 | $ 1.42 | 1.31 % | $ 235 M | France |
 |
BeiGene, Ltd.
BGNE
|
3.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
Inventiva S.A.
IVA
|
-40.69 | $ 5.05 | -1.66 % | $ 138 M | France |